Navigation Links
New analysis shows DAYTRANA offered ADHD symptom control for 12 months
Date:5/7/2008

Washington, D.C. May 7, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD). The findings from the analysis reaffirmed that DAYTRANA has an established safety profile and effectively controlled ADHD symptoms in both boys and girls for the duration of the study. Results from this analysis were presented today at a national scientific medical meeting in Washington, D.C.

This analysis further demonstrates that DAYTRANA has a recognized safety profile and is an effective treatment for ADHD symptoms in both boys and girls with the disorder, said Robert Findling, M.D., investigator of the analysis and Director of the Division of Adolescent and Child Psychiatry at University Hospitals Case Medical Center and Professor of Psychiatry at Case Western Reserve University. The findings are significant because only a relatively modest amount of work has been done to examine the effects of ADHD treatments by gender. This is an important consideration for parents because not only do they need to recognize that ADHD symptoms present differently in girls than in boys, but also because it is important to understand the role of treatment for both sexes.

According to the U.S. Centers for Disease Control and Prevention (CDC), a national survey conducted in 2003 showed that 11 percent of boys have been diagnosed with ADHD, in contrast to 4.4 percent of girls. Additional studies suggest the prevalence of ADHD in girls is critically underestimated and that many school-aged girls with the disorder are undiagnosed and under treated. This may be due to the fact that girls tend to show less disruptive ADHD symptoms such as inattention (e.g., inability to focus, organize and finish tasks), while boys tend to exhibit disruptive symptoms such as hyperactivity and impulsivity (e.g., restlessness, interrupting, impulsive decisions). In children, ADHD may interfere with paying attention in school, completing homework or making friends. Difficulties experienced by these children may continue into adulthood.

Summary of Analysis Findings

This analysis was conducted using data from an open-label, flexible dose, 12-month extension study in which 326 children received DAYTRANA. Children who enrolled in this study previously participated in other studies in which they received DAYTRANA, osmotic-release oral system (OROS) methylphenidate or placebo as part of the study design. The primary objective of this study was to investigate the long term safety profile of ADHD treatment with DAYTRANA, and the secondary objective examined the efficacy of the medication between genders. This subanalysis was conducted to examine treatment differences between boys and girls receiving DAYTRANA.

Adverse events were reported in a higher percentage of boys than girls in all dose groups; however, they were generally comparable between genders. Further, no clinically significant differences in adverse events were noted between boys and girls. Adverse events were typically mild or moderate and consistent with stimulant treatment. The most common adverse events included decreased appetite, headache, upper respiratory tract infection, cough, fever and decreased weight.

In the study, the efficacy of DAYTRANA was measured using the ADHD Rating Scale (ADHD-RS-IV), the Clinical Global Impressions-Improvement (CGI-I) scale and the Parent Global Assessment (PGA) rating scale and measurement results were found to be statistically significant on all scales. In the analysis, boys had a 41 percent change on the ADHD-RS-IV (as calculated from a mean baseline score of 11.6, with a mean change from baseline to endpoint of -4.8) and girls had a 23 percent change on the scale (as calculated from a mean baseline score of 11.3, with a mean change from baseline to endpoint of -2.6). Lower scores on the ADHD-RS-IV reflect an improvement in symptom control.

On the CGI-I scale, clinicians rated 83 percent of boys and girls improved or very much improved at the end of the study compared to week one. Additionally, the PGA rating scale showed that 78 percent of boys and girls improved or very much improved at the end of the study compared to week one. The results in both the CGI-I and PGA scale were comparable between boys and girls.

Dr. Findling added, These positive findings, along with previously presented research, reinforces that the ADHD patch is an important treatment option for children, especially those who may benefit from an ADHD medication that can accommodate their changing daily needs.

DAYTRANA is the first and only non-oral medication for treating ADHD in children aged 6 to 12 years. Parents can adjust the wear time up to 9 hours under the physicians advice to accommodate for their childs varying weekdays, weekend and vacation schedules. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.


'/>"/>

Contact: Alana Brier
Alana.Brier@porternovelli.com
203-565-3980
Porter Novelli
Source:Eurekalert

Related medicine news :

1. PA Governor Says Financial Analysis Shows Nothing Stands in Way of Senate Action to Help Pennsylvanias Uninsured
2. Analysis of alcoholics brains suggests treatment target
3. New Lewin Group Analysis: Medicare Cuts for Nursing Facility Care Could Have Economic Impact Up to $4.2 Billion, Threaten Jobs
4. Carnegie Mellon technique accelerates biological image analysis
5. New analysis finds daycare attendance early in life cuts childhood leukemia risk by 30 percent
6. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
7. Invention gives improved gene technology analysis
8. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
9. Genome analysis reveals new protein associated with breast cancer progression
10. Analysis Highlights Economic Contribution of Hospitals to Communities
11. SAIC Awarded DIA Intelligence Analysis Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: